To study the effect of oral oleoyl-estrone on the plasma lipoprotein profile and tissue lipase activities in order to determine the handling of circulating lipids by adipose tissue, liver and muscle of obese female rats. DESIGN: Lean (Fa=?) and obese (fa=fa) female Zucker rats treated for 10 days with a daily gavage of 0.2 ml sunflower oil containing 0 (controls) or 10 mmol=kg of oleoyl-estrone. After sacrifice, samples of tissues and plasma were taken. MEASUREMENTS: Plasma lipoprotein classes and composition; lipoprotein lipase and hepatic lipase activities in plasma, liver, skeletal muscle and periovaric and mesenteric white adipose tissue (WAT). RESULTS: Oleoyl-estrone decreased plasma cholesterol (mainly in HDLs: 76%) of lean rats, but dramatically decreased all lipid classes in obese rats, in which chylomicra and VLDL lost most of their triacylglycerols (95 and 81%, respectively). Hepatic lipase activity decreased markedly with oleoyl-estrone in all groups, both in plasma (79% lean, 100% obese) and liver (62% in both groups). Lipoprotein lipase activity was largely unchanged by oleoyl-estrone in lean rats, but in the obese it decreased in WAT (82% in periovaric, and 49% in mesenteric), and increased in plasma (Â4) and in skeletal muscle (Â5); liver levels showed no change. CONCLUSIONS: The shift observed in obese rats from a decrease in liver and WAT lipoprotein lipase and hepatic lipase activities to an increase in muscle lipoprotein lipase is coincident with the hypolipemic effect of oleoyl-estrone, especially in obese rats, and indicates that muscle is a key site for the disposal of endogenous fat mobilized due to oleoyl-estrone treatment.
Introduction
Body weight is maintained through a tightly controlled homoeostatic system as portrayed in the lipostatic model, 1 in which the hypothalamic centres that control appetite and energy expenditure receive periodic information about the size of the body fat stores through a blood-borne metabolic or hormonal signal. 2 -4 Oleoyl-estrone has been postulated as a lipostat signal 5, 6 since its levels are highly correlated with body fat stores in normal-weight humans 7 and its administration to experimental animals modifies the body weight reference setting. 6 Oleoyl-estrone elicits a loss of fat, while body protein is preserved. 8 This is accomplished by decreasing appetite but maintaining energy expenditure. 5 The loss of fat is dosedependent, 9 and independent of sex, 10 and of the mode of administration, ie continuous i.v. injection, 5 oral gavage 9, 10 or dispersed in the food. 8 A large proportion of oral oleoylestrone is absorbed unaffected by the digestive process and transferred to lipoproteins. 11 The effects of oleoyl-estrone are not mimicked by free estrone, which induces fat deposition and growth. 12 Thus, free estrone reverts the actions of oleoylestrone; the nature of the fatty acid moiety is critical for its slimming effectiveness. 13 In the rat, oleoyl-estrone is found in large concentrations in adipose tissue and lipoproteins. 14 Oleoyl-estrone reduces the size of white adipose tissue (WAT) cells. 15 This process requires the transfer of fatty acids from WAT to other tissues, such as the liver, and from this organ to all other tissues able to use lipoproteins and oxidize the resulting fatty acids. However, oleoyl-estrone decreases circulating plasma lipids, 16 especially cholesterol and phospholipids, also inducing small decreases in triacylglycerols and slight change in free fatty acids and ketone bodies. 6, 16 On the other hand, the overall loss of fat and decreased energy intake clearly indicates that oleoyl-estrone-treated rats oxidize significant amounts of fat from their WAT stores; respiratory quotient measurements agree with this interpretation. 5, 17 However, neither the site of this oxidation nor the mechanism of lipid transport are known.
The study of thermogenic indicators, such as the expression of uncoupling proteins, 17, 18 suggests that brown adipose tissue (BAT) cannot account for the main share of the fat disposal, since BAT thermogenesis does not increase, at least not sufficiently to explain the massive oxidation of fat stores. 17 Here we examine the hypothesis that either liver or skeletal muscle accounts for this increased loss of fat. Most of the energy provided by WAT stores is taken up in the form of free fatty acids by the liver. 19 Since their plasma levels are unaltered, we can assume that the liver takes them up at sustained high rates, and either oxidizes them or converts them to ketone bodies, or incorporates them into VLDL triacylglycerols. The lack of increase in circulating ketone bodies, together with maintained glycaemia, liver glycogen and liver lipids under oleoyl-estrone treatment 6, 16 further suggest that most of the WAT-derived fatty acids find their way into VLDLs. This prompted us to analyse the proportions and chemical composition of circulating lipoproteins. We previously studied the changes in lipoprotein size and composition elicited by genetic obesity, and found that the Zucker fa=fa rat tends to present larger lipoprotein particles, 20 which remain for longer and are not easily disposed of by tissue lipases. 21, 22 This is probably a consequence of altered lipoprotein structure caused by apolipoprotein deficits 20 rather than due to a lack of lipoprotein lipase activity in peripheral tissues. 23 The key for VLDL utilization is lipoprotein lipase (EC 3.1.1.34). Thus, in addition to lipoprotein profiles, we measured the effects of oleoyl-estrone on the levels of this enzyme in plasma, and in organs and tissues with high energy turnover, such as liver, muscle and adipose tissue. We also included hepatic lipase (EC 3.1.1.3) to discern the role of liver in the disposal of the lipoprotein-carried lipid energy released by oleoyl-estrone treatment.
Methods

Animals and treatment
Twelve female adult Zucker lean (Fa=?) and 12 obese (fa=fa) rats, aged 12 weeks, were maintained in standard conditions (lights on from 08:00 to 20:00); they were fed on a standard maintenance pellet (B&K, Sant Vicent dels Horts, Spain) with a gross energy content (measured using a bomb calorimeter: C-7000, IKA, Heitersheim, Germany) of 15.96 MJ=kg, and metabolizable energy of 13.73 MJ=kg (calculated from standard values of its main components); 70.7% of the energy was derived from carbohydrate, 22.2% from protein, and 7.1% from lipids. The animals were given a daily gavage (between 08:00 and 09:00) of 0.2 ml of sunflower oil through a stomach tube. Six lean and six obese animals received the gavage containing oleoyl-estrone at a dose of 10 mmol per kg of body weight per day; 9,10 the rest of rats (controls) received the oil gavage alone.
The rats were weighed daily, and their food consumption was measured. After 10 days of treatment, the rats were killed by decapitation at the beginning of a 12 h light cycle. The blood was collected in beakers containing dried EDTA-Na. Plasma was immediately obtained by centrifugation and then used for lipoprotein separation and enzymatic analyses. Samples of liver and WAT from mesenteric and periovaric locations, and samples of hind leg muscle were then immediately dissected, frozen in liquid nitrogen and kept at 780 C until processed. Glucose levels were also measured (Glucocard Memory, Menarini Diagnostics, Firenze, Italy) in the blood at the time of death.
Lipoproteins and lipids
Lipoproteins in fresh plasma were fractionated by differential ultracentrifugation in known-density media obtained through the addition of KBr. 24 Five main fractions were obtained: chylomicra, very low density lipoproteins (VLDL), low density lipoproteins (LDL), high density lipoproteins (HDL) and the remnant lipoprotein-depleted plasma (LPdp). 24 These fractions were used for the analysis of protein and lipid components, and for the estimation of particle size.
Whole plasma, lipoprotein fractions and LPdp were used for the analysis of protein and lipid content. Total protein was estimated with the Bradford method. 25 Total cholesterol was measured in saline with a high-performance cholesterol kit (139050 Roche, Mannheim, Germany). Triacylglycerol concentrations were measured with a commercial kit (COD11528 Biosystems, Barcelona, Spain) and the results were corrected for free glycerol. Phospholipids were quantified by a choline-based method (PLMPR2 691844, Roche).
Activity of lipases
Liver, muscle and WAT samples were homogenized, using an Ultra Turrax T25 (IKA, Heitersheim, Germany) tissue blender, in 10 mM HEPES buffer pH 7.5, containing 250 mM sucrose, 1 mM EDTA and 1 mM dithiothreitol in order to measure lipoprotein lipase activity in tissues. Homogenates were clarified by centrifugation (10 min at 10 000 g) at 4
C. The assay mixture (pH 7.5) contained 0.6 mM tri-[9, 10 (n)- C) rat serum, 25 mM PIPES buffer and 0.02 ml of sample in a final volume of 0.2 ml; the incubation was carried out for 30 min at 25 C; 26 after the reaction was stopped, the [ 3 H]-oleate evolved was quantified. 27 All measurements of lipoprotein lipase activity in plasma and liver homogenates were carried out in the presence of anti-rat hepatic lipase antiserum. 28 The homogenate and plasma protein content were determined with the Bradford method. 25 Hepatic lipase activity was determined in liver and plasma by the method of Ehnholm et al 29 with minor modifications. The assay mixture (pH 8.5) contained 2.5 mM 3 H-trioleoylglycerol, 0.75 M NaCl, 30 g=l bovine serum albumin (fatty acid-free), 50 mM tris buffer and 0.05 ml of sample in a final volume of 0.2 ml. Incubation conditions, and the quantification of [ 3 H]-oleate released were as in the lipoprotein lipase assay.
The overall share of potential activity of the enzymes studied was also estimated by determining the contribution of each organ=tissue (ie plasma, liver, muscle and WAT) enzyme activity in relation to body mass; these results are expressed as the total activity found in a given tissue or compartment. Liver weight was directly estimated; the mass of plasma was taken as 2.75% of body weight, since blood is 5% of body weight, 30 and plasma volume is 55% of blood. Overall WAT lipoprotein lipase activity in both groups of animals was calculated using the mean periovaric and mesenteric data for each animal and the proportions of WAT estimated for lean (15% of body weight) 31 control and oleoyl-estrone-treated (7%) 9 and obese Zucker fa=fa rats (35%) 32 control and oleoyl-estrone-treated (28%); 10 muscle mass was also calculated as a proportion of body weight -43% for lean 33 and 33% for obese rats. 22 Statistical analysis of the differences between groups was established using ANOVA programs and Student's t-test, with the limit of significance set at P < 0.05. All data were tested with the w 2 test (none was excluded) for deviations from the normal distribution.
Results
Treatment with a daily oral gavage of oleoyl-estrone resulted in the decrease of body weight in lean and -more markedly -in obese rats (Figure 1 ). Obese controls ate more food per day than lean controls: 22.2 AE 1.2 vs 14.3 AE 1.7 g=day (Â1.6; P < 0.05); oleoyl-estrone resulted in a lower food intake in lean rats (mean food intake 10.4 AE 1.1 g=day; 73%, P < 0.05) and in a more marked and increasing loss of appetite in the obese, which consumed 8.1 AE 2.3 g=day (36%, P < 0.05).
Blood glucose levels at the time of death were 4.44 AE 0.09 and 3.74 AE 0.25 mM (NS) in lean controls and oleoylestrone-treated animals, respectively; in obese rats, the corresponding values were 4.54 AE 0.10 and 4.81 AE 0.16 mM; no significant differences were observed between controls and treated groups.
Oleoyl-estrone treatment deeply affected plasma lipids in both lean and obese rats (Table 1 and Figure 2) . In lean rats, oleoyl-estrone induced little change in lipoprotein composition, affecting essentially the HDL fraction, in which cholesterol decreased most (74%), which was reflected in the lower whole plasma cholesterol levels of lean treated rats (64%), followed by HDL phospholipid (48%).
Control obese rats showed higher triacylglycerol, phospholipid and cholesterol levels than lean controls, an effect observed in total plasma (Â3.2, Â1.7 and Â1.5, respectively) and chylomicra (Â5.4, Â5.7 and Â3.9, respectively). VLDLs also presented higher triacylglycerols (Â1.7) and phospholipids (Â2.7), LDLs had higher cholesterol (Â2.8), and HDL showed higher phospholipids (Â2.3) and cholesterol (Â1.9) in obese than in lean controls. Oral oleoyl-estrone treatment M Blay et al
In obese rats, treatment with oleoyl-estrone induced marked decreases in all chylomicra (protein decreased 52%; triacylglycerols 95%; phospholipids 92%, and cholesterol 95%) and VLDL components (protein decreased 88%; triacylglycerols 81%; phospholipids 91%, and cholesterol 95%); in LDLs only tricylglycerol levels decreased (70%) and in HDLs all components decreased again with treatment (protein decreased 27%; phospholipids 62%, and cholesterol 76%), except for triacylglycerols (increased 30%). This resulted in markedly lower levels of all lipid classes in whole plasma of obese treated rats compared with their controls (triacylglycerols decreased 83%; phospholipids 57% and cholesterol 68%).
When both oleoyl-estrone-treated groups (lean and obese) were compared, in chylomicra and VLDL, both protein and triacylglycerols showed lower levels in the obese than in lean animals (decreased 51 and 74%, respectively in chylomicra, and 71 and 75% in VLDL), as well as in VLDL phospholipids (decreased 88%). In contrast, HDL triacylglycerol levels in treated obese rats were higher than in the lean (Â23), and no differences were observed in LDLs.
Lipoprotein-depleted plasma composition did not differ significantly because of obesity; oleoyl-estrone induced only a decrease in total phospholipid levels in lean (29%) and obese (49%) animals. Table 2 shows the lipase activities in plasma, liver, WAT and muscle of lean and obese rats following treatment with oleoyl-estrone compared with controls. In lean rats, oleoylestrone treatment did not significantly affect the lipoprotein lipase activity of the tissues studied, with the exception of a generalized rise (Â3.6) in plasma. Obese controls showed similar plasma and tissue lipoprotein lipase activity to lean controls. Oleoyl-estrone treatment of obese rats, however, resulted in decreases in lipoprotein lipase activity of periovaric WAT (decreased 33%), no significant changes in mesenteric WAT or liver, and increases in plasma (Â4.0) and muscle (Â5.2).
Obese controls showed lower plasma hepatic lipase (41% of controls) and similar liver hepatic lipase activities to lean controls. Oleoyl-estrone treatment, however, provoked a marked decrease in the liver levels of hepatic lipase, both in lean (62%) and obese rats (62%). In plasma, the decrease was even more marked: 79% in controls and 100% in the obese. Hepatic lipase activity was not detected in the oleoylestrone-treated obese rats plasma. Figure 3 depicts the overall changes in lipases of control and treated rats corrected for organ and rat size to facilitate comparison. Obesity did not affect hepatic lipase activity, but oleoyl-estrone induced a 61% decrease in lean and 62% in obese rats. Obese rats had more lipoprotein lipase in WAT Figure 2 Changes in plasma lipids of lean and obese rats receiving a daily gavage of oleoyl-estrone (10 mmol=kg=day). The data were calculated from those in Table 1 , and are the mean AE s.e.m. of lipid classes expressed in g=l of whole plasma. Total cholesterol mass is expressed as non-esterified cholesterol equivalents. CM ¼ chylomicra; LPdp ¼ lipoprotein-depleted plasma.
Oral oleoyl-estrone treatment M Blay et al Oral oleoyl-estrone treatment M Blay et al per kg of rat weight than the lean (Â1.5), although the differences were practically nil when treated groups were compared. WAT lipoprotein lipase decreased following oleoyl-estrone treatment (55% in lean and 75% in obese rats). The contribution of liver to overall lipoprotein lipase activity was minimal and unaffected by obesity and=or oleoyl-estrone. Muscle lipoprotein lipase was higher in the obese than in the lean both in controls (Â1.4) and especially following oleoyl-estrone treatment (Â9.5); in these animals, muscle lipoprotein lipase partly compensated the loss of WAT lipoprotein lipase; the contribution of muscle lipoprotein lipase increased from about 6% of that of WAT in controls to roughly the same activity in both WAT and muscle in oleoyl-estrone-treated obese rats.
Discussion
Oleoyl-estrone had markedly different effects on lipases of lean and obese rats. In lean, no significant changes in tissue lipoprotein lipase were observed, except for a rise in the activity of plasma, accompanied by a generalized decrease in hepatic lipase. The decreased ability of the liver to metabolize triacylglycerols is consistent with its role in the handling of the reverse process occurring during oleoyl-estrone treatment, ie taking up the products of WAT lipolysis and reshaping them into VLDLs for export to other tissues. There is no need for increased triacylglycerol-handling ability in the liver when little exogenous fat is available following oleoylestrone treatment, since food intake decreases and WAT lipid mobilization increases. 5, 9 However, the loss of adipose tissue resulted in the overall loss of lipoprotein lipase activity in the whole rat to about half of that of controls. Oleoyl-estrone induced a marked loss in body energy -up to 1% of the body energy content being lost daily in the same experimental conditions, mainly in the form of lipid. 8, 9 However, the lack of tissue changes in lipoprotein lipase (and even its overall decrease) suggests that the amount of enzyme available in the tissues was enough to allow for the flow of lipid from WAT to liver and thence to other tissues such as muscle.
The high lipoprotein lipase activity observed in the WAT of obese rats agrees with previous findings, 23 and contrasts with the limited ability of obese rats to dispose of chylomicra 21 and the maintenance of high concentrations of lipids in plasma. 34 The abnormal size, composition and apoprotein distribution of obese rat lipoproteins 20 can account for the inability of existing lipoprotein lipase to cope with the circulating lipid load. This in turn may trigger higher increases in lipoprotein lipase and hepatic lipase expression as a counter-regulatory measure to keep lipids out of the plasma and channel them into tissues. 35 The marked differences observed in two locations of visceral fat in tissue content and in their response to oleoyl-estrone point to a wider diversity of WAT function according to location. 36, 37 The high lipoprotein lipase activity and marked response to oleoyl-estrone of mesenteric WAT suggests that its splanchnic location may confer upon this tissue a higher metabolic control of lipid (essentially dietary) handling, than the simple storage depot function of other WAT locations, such Figure 3 Lipoprotein-lipase and hepatic lipase activities present in the organs and tissues of Zucker lean and obese rats receiving a daily gavage of 10 mmol=kg=day of oleoyl-estrone compared with controls. Enzyme activity data are expressed in absolute terms referred to the whole of the given organ and corrected by the size of the rat (ie nkat in all muscle or WAT or liver tissue per kg of rat weight). Units: 1 nkat (nanokatal) ¼ amount of enzyme activity corresponding to the hydrolysis of 1 nmol of ester bonds per second. The data were calculated from rat and organ weights and the data in Table 2 , and are the mean AE s.e.m. of five or six different animals. Plasma data were not included because of their scant contribution to overall lipase activity. The WAT data are an estimation of the activity present in the tissue, calculated using the mean between the corresponding periovaric and mesenteric values as activity per gram of tissue. L-C ¼ lean controls; L-OE ¼ lean OE-treated; O-C ¼ obese control; O-OE ¼ obese OE-treated. Statistical analysis: comparison between control and OE groups; *P < 0.05; comparison between lean and obese groups, d P < 0.05.
Oral oleoyl-estrone treatment M Blay et al as the periovaric fat mass. This diversity of response because of the location of the WAT sampled can be reconciled with conflicting reports on the effect of obesity on lipoprotein lipase activity of WAT. 23,38 -41 In lean rats, muscle lipoprotein lipase was unchanged by oleoyl-estrone treatment, its activity being only a small fraction of that of WAT. However, in the obese, the already high basal activity increased four-fold under oleoyl-estrone treatment. The large mass of muscle compounded this effect, magnifying the lipolytic share of this organ with respect to the overall lipolytic activity, in the end matching that of WAT. This indicates that, following oleoyl-estrone treatment in the obese rats, muscle acquired a higher protagonism in the handling of lipids; this is in agreement with its higher UCP3 expression 18 and the improvement of hyperlipidemia 10 as observed here. Muscle thus appears to be a key site for lipid disposal in the oleoyl-estrone treated obese rat.
WAT acts as a metabolic sink for the excess energy (mainly lipids) not being used elsewhere. 42 In WAT, fat storage increased in parallel to tissue lipoprotein lipase activity in obese rats, both processes being dependent on high insulin levels. 41, 43, 44 High WAT lipoprotein lipase and hepatic lipase can be found in the obese 43 in conjunction with hyperlipidaemia. 34, 45 This may be partially due to the lack of effectiveness of lipoprotein lipase in muscle and other tissues against altered lipoproteins such as those found in obese rats. 20 The increase in muscle lipoprotein lipase, and the decreases in hepatic lipase and WAT lipoprotein lipase induced by oleoyl-estrone treatment changed the main site for lipoprotein-carried lipid disposal in the obese rat: from WAT and liver to skeletal muscle. This shift also helped to normalize plasma lipids, 10 and lipoprotein size and lipid content 14 in oleoyl-estrone-treated animals. The dramatic decrease in hepatic lipase shows that oleoylestrone treatment reverses the flow of lipids through the blood and its handling by the liver: in the obese, lipid is used and stored by liver and WAT; in oleoyl-estrone-treated rats, WAT loses fat, the liver simply handles non-esterified fatty acids and sends them back as lipoproteins (but neither is using lipoprotein-carried triacylglycerols because of low lipase levels), and only the muscle uses actively these triacylglycerols exported from liver and WAT.
Lipoprotein lipids increased in the obese control rats when compared with their lean counterparts, as previously described, 20 the differences being mainly due to the accumulation of free and esterified cholesterol as well as triacylglycerols, especially accumulated in the chylomicra and HDL fractions. 20, 33 Oleoyl-estrone treatment decreased triacylglycerol and total cholesterol plasma levels, in agreement with previous findings. 10, 16 However, the changes elicited by oleoyl-estrone were different in lean and in obese rats. In the former, most of the change was attributable to HDL, the lipid content of which decrease by almost two thirds, with only limited change, if any, in the other plasma lipoprotein fractions. In the obese rats, however, the reduction of circulating lipids was more intense, resulting not only in the loss of cholesterol and triacylglycerols, but also in the loss of phospholipid, affecting all lipoproteins studied and not only the HDLs as in lean rats. The decrease in triacylglycerols found in treated obese rats mainly affected the larger lipoproteins: chylomicra and VLDL. This decrease may be caused by the increased skeletal muscle lipoprotein lipase activity observed. The relative maintenance of circulating triacylglycerol levels in oleoyl-estrone-treated lean rats compared with controls also agrees with this interpretation, since muscle lipoprotein lipase did not increase in lean rats with oleoylestrone treatment, and these changes occurred in conditions of decreased hepatic and WAT lipase activity.
The massive loss of lipoprotein cholesterol induced by oleoyl-estrone treatment in both lean and obese rats may be a consequence of the improved cholesterol handling induced by oleoyl-estrone. This may be, at least in part, a consequence of the increased lipoprotein lipid turnover we postulate. Nevertheless, the disappearance of cholesterol from plasma indicates an alternative sink. Since in the conditions studied there are no special cholesterol needs for growth or cell differentiation, the most probable cholesterol sink would be the liver, where excess cholesterol is disposed of 46 through chemical modification and=or bile excretion. 47 These results reveal the effects of oleoyl-estrone on plasma lipids, normalizing their levels in hyperlipidemic animals, but hardly affecting the normolipidemic. The lipid displaced from adipose tissue by oleoyl-estrone-induced endogenous lipid mobilization, and not found in plasma, was largely consumed by muscle. Preferential alternative lipid oxidation in this tissue may also help explain the maintenance of plasma glucose within the normal range in the presence of slightly elevated liver glycogen levels, as found in oleoylestrone-treated rats. 6, 16 The more efficient utilization of lipidic substrates and the preservation of glucose, probably helped maintain low energy intake and prevent ketogenesis in spite of the availability of fatty acids.
